Today Asensio & Company, Inc. released a 5 page report with 43 exhibits on the ongoing congressional investigation of the American Stock Exchange’s (“AMEX”) listing requirements, which resulted from the AMEX’s failure to de-list Hemispherx Biopharma, Inc. (Symbol: HEB) (Price: $3.92). HEB is a criminally organized company listed on the AMEX. The blatancy of HEB’s fraudulent conduct, and the AMEX’s failure to protect investors, led to the AMEX congressional investigation. AMEX leaders have received HEB shares. The AMEX chose to investigate HEB short sellers. No HEB short selling violations were ever found. The congressional report severely criticizes the AMEX. The report provides conclusive and highly damaging evidence of very questionable relationships between HEB and leaders of the AMEX. The new HEB report and all of its exhibits are available on the front page at www.asensio.com, or through the link listed below:
HEB is being investigated for fraud by the SEC, and has been the subject of at least two congressional medical and securities fraud investigations. William A. Carter (“Carter”) was HEB’s leader when HEB made payments and executed transactions that are the subject of at least 6 federal criminal indictments and numerous New York State indictments. Over the past 25 years, Carter has been accused of unethical and illegal behavior by HEB itself who he sued, of extortion by an AIDS patient who he then sued, of scientific fraud by E.I. Dupont who he then sued, of improper medical work by a hospital and his own medical research staff who he then sued. Carter has also sued investors who lent him money, lawyers who sought to represent HEB’s harmed investors and a hospital that sought to terminate its relationship with HEB. Specifically, Carter was found by the hospital to have inappropriately hired a private investigator, to have secretly filmed a medical graduate student, and was accused of improperly conducting medical experiments funded by grants. After being given one year to find a new job Carter was finally fired by the hospital. Carter then sued the hospital and made charges against his co-workers including the graduate student. The European Medical Evaluation Authority (“EMEA”) denied HEB’s only request for Ampligen marketing authorization in its 30-year history. The EMEA found that HEB’s Ampligen research offered “no real pharmaceutical development”. The EMEA also found that the results of HEB’s Ampligen research “are not useful for efficacy assessment” and that “the Ampligen safety profile is poorly documented”. In its 6 years as a publicly traded company HEB has used a series of false press releases to defraud investors. HEB’s entire stock value is based on its public promotion of the commercial value of Ampligen that is based on questionable out-dated studies.
Asensio & Company, Inc. is actively engaged in short selling and advises its clients on securities it believes are overvalued. A complete documented history of Asensio’s published work with short-selling transactions, and the firm’s definition of gross overvaluation, is available on the Internet at www.asensio.com. Short selling involves a risk not associated with the purchase of stock including, but not limited to, unlimited loss and stock borrowing risks. John Wiley & Sons, Inc. has published a book about Asensio & Company’s short selling titled “Sold Short: Uncovering Deception in the Markets.” The book can be ordered on the Internet at www.asensio.com and www.wallstreetbabylon.com, or www.amazon.com. Additional information is available upon request.